Pay in 4 interest-free payments of $20.00 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
InChi: InChI=1S/C27H30F3N9O/c1-17(38-8-10-39(11-9-38)25(40)15-27(28
GS5734-metabolite
Solubility: DMSO: 6 mg/mL(9
InChiKey: KBXLMOYQNDMHQT-QGZVFWFLSA-N
Smiles: C[C@@H]1CC=CC=CC=CC=C[C@@H](C[C@@H]2O[C@@](O)(C[C@H](O)[C@H]2C(O)=O)C[C@@H](O)C[C@H]2O[C@@H]2C=CC(=O)O1)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](N)[C@@H]1O |t:3
Foretinib 603oglibose InChi: InChI=1S/C27H30F3N9O/c1-17(38-8-10-39(11-9-38)25(40)15-27(28Foretinib, also known as XL880 and GSK1363089, is an orally bioavailable small molecule with potential antineoplastic activity. MET VEGFR2 inhibitor GSK1363089 binds to and selectively inhibits hepatocyte growth factor (HGF) receptor c MET and vascular endothelial growth factor receptor 2 (VEGFR2), which may result in the inhibition of tumor angiogenesis, tumor cell proliferation and metastasis. The proto oncogene c MET has been found to be over